Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00692172 | Open-label Study to Evaluate Safety of Multiple Courses of IM Alefacept During Treatment of Chronic Plaque Psoriasis | PHASE3 | COMPLETED | 175 | — | — | Dec 1, 2001 | Nov 1, 2004 | Sep 18, 2014 | 43 | United States, Belgium +7 |
| NCT00301002 | Study to Evaluate the Efficacy of Alefacept to Treat Palmar Plantar Pustulosis | PHASE2 | COMPLETED | 15 | — | — | Jun 1, 2005 | Oct 1, 2006 | Nov 23, 2006 | 1 | Canada |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Alefacept | DRUG | intramuscular injection (IM) |
Inclusion Criteria: * Must have received at least 8 injections in the C99-717 study and completed the final follow-up visit OR, * Must have completed the C99-712 study and been in C99-717 interim visits at the time dosing in the C99-717 study was closed. A subject who completed C99-712 but did not ...